Galapagos To Buy Inpharmatica

Galapagos NV (Euronext & AIM: GLPG) has agreed to acquire Inpharmatica Ltd., a UK-based provider of genome-scale predictive products and services for drug discovery research. The total deal is valued at up to Euro 19.1 million, including a Euro 6.5 million upfront cash payment. Inpharmatica has raised around $75 million in VC funding since 1998, from firms like 3i Group, Abingworth Management, Advent Venture Partners, August Equity, GIMV, Gilde, Reed Elsevier Ventures, Unibio Ltd., Genentech and Vertex Management. www.glpg.com www.inpharmatica.co.uk